|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Research and development incentives | |||||
| Investment income | |||||
| Interest expense on finance lease liability | |||||
| Interest expense on debt obligations | |||||
| Other expense | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| Income tax (benefit) provision | |||||
| Net loss | |||||
| Net loss per common share, basic (in dollars per share) | |||||
| Net loss per common share, diluted (in dollars per share) | |||||
| Weighted average common shares outstanding, basic (in shares) | |||||
| Weighted average common shares outstanding, diluted (in shares) | |||||
Loading...